Carole Augustine

Driven by a dedication to patients, Carole Augustine has devoted 23 years to the pharmaceutical industry and is passionate about advancing innovative health solutions. As a pillar of Otsuka’s R&D business, Carole has led multiple CNS programs in her role in clinical management, built effective global teams and played a key role in several facets of the R&D business since joining Otsuka in 2005.

As Vice President, R&D Shared Sciences at Otsuka, Carole is responsible for overseeing Portfolio Strategy & Asset Management, Global Quality and Data and Analytics. These functions are at the foundation of everything OPDC delivers. Carole’s leadership will help harmonize and focus the R&D organization on producing quality outcomes aligned with our strategic plan and leverage our data to better understand our patient’s journeys and optimize our products.

While at Otsuka, Carole has played a key role in the REXULTI® (brexpiprazole) MDD program, dual NDA submission and subsequent FDA inspection. She was instrumental in the launch of the first FDA-approved digital medicine, drug-device combination product. Most recently, Carole served as Vice President, R&D Portfolio Strategy & Asset Management where she oversaw management of all assets within the company’s Digital, Nephrology/ Immunology and CNS portfolios.

Prior to joining Otsuka, Carole held various positions in clinical research in the pharmaceutical industry, including a five-year stint at Shire where she worked on a clinical team to develop several compounds for the treatment of both pediatric and adult ADHD. In addition to her pharmaceutical experience, Carole spent nearly 10 years working at Quintiles Transnational (now IQVIA) and Parexel International, where she worked in multiple therapeutic areas including neuroscience and anti-infectives.

Carole lives in Alexandria, Virginia with her husband and two college-aged children.